A Discussion About a Hematology Career in Industry With Drs. Benjamin Kim and Mark Chao
Dr. Benjamin Kim and Dr. Mark Chao discuss what it's like for a hematologist holding an industry position.
Predicting Responses to Gemtuzumab Ozogamicin
Dr. Raetz looks at the use of gemtuzumab ozogamicin (CO) for the treatment of acute myeloid leukemia in adults and children.
Patients with de novo acute myeloid leukemia (AML) typically come to clinical attention with symptoms of bone marrow failure in the absence of any prior hematologic condition. In many such patients, the diagnosis is sudden and unexpected, without any significant prodrome. The generally poor prognosis of AML and the decades-long impasse in generating effective therapeutic strategies other than conventional antracycline and cytarabine-based (“3+7”) induction chemotherapy has spurred intense investigation of its molecular and cellular origins. Pioneering work by numerous investigators led to an early understanding of the genetics of AML, particularly the identification of recurrent chromosomal abnormalities and mutations in the genes FLT3 and NPM1. However, it is only with the recent implementation of massively parallel next-generation DNA sequencing that the full spectrum of mutations in AML has been defined.
November-December 2017Volume 14, Issue 6
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology